Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Bean N. Anyang"'
Autor:
Ethan Dmitrovsky, Konstantin H. Dragnev, Sarah J. Freemantle, Yongli Guo, James DiRenzo, Hua Li, Jonathan M. Kurie, Gregory J. Tsongalis, David Johnstone, William Nugent, Bean N. Anyang, Jan H. Beumer, Lorenzo Sempere, Fadzai Chinyengetere, Vincent Memoli, Cherie P. Erkmen, Fabrizio Galimberti, Tian Ma
PDF file - 59K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293233d2b9247ba7f22547e289c26ff4
https://doi.org/10.1158/1535-7163.22499758
https://doi.org/10.1158/1535-7163.22499758
Autor:
Ethan Dmitrovsky, Konstantin H. Dragnev, Sarah J. Freemantle, Yongli Guo, James DiRenzo, Hua Li, Jonathan M. Kurie, Gregory J. Tsongalis, David Johnstone, William Nugent, Bean N. Anyang, Jan H. Beumer, Lorenzo Sempere, Fadzai Chinyengetere, Vincent Memoli, Cherie P. Erkmen, Fabrizio Galimberti, Tian Ma
PDF file - 652K, Supplemental Fig. 1: The structure of vorinostat (SAHA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105a4f3d2ef3685b4cb5999e5e2e61e2
https://doi.org/10.1158/1535-7163.22499770
https://doi.org/10.1158/1535-7163.22499770
Autor:
Ethan Dmitrovsky, Konstantin H. Dragnev, Sarah J. Freemantle, Yongli Guo, James DiRenzo, Hua Li, Jonathan M. Kurie, Gregory J. Tsongalis, David Johnstone, William Nugent, Bean N. Anyang, Jan H. Beumer, Lorenzo Sempere, Fadzai Chinyengetere, Vincent Memoli, Cherie P. Erkmen, Fabrizio Galimberti, Tian Ma
PDF file - 3079K, Supplemental Fig. 3: Paired pre-treatment versus post-vorinostat treatment biopsies from a lung cancer probed for p21 immunohistochemical expression. These representative biopsies from case 7 revealed an increase in p21 levels in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46fd67fc10c14250c1ed28aba3c001ed
https://doi.org/10.1158/1535-7163.22499761
https://doi.org/10.1158/1535-7163.22499761
Autor:
Ethan Dmitrovsky, Konstantin H. Dragnev, Sarah J. Freemantle, Yongli Guo, James DiRenzo, Hua Li, Jonathan M. Kurie, Gregory J. Tsongalis, David Johnstone, William Nugent, Bean N. Anyang, Jan H. Beumer, Lorenzo Sempere, Fadzai Chinyengetere, Vincent Memoli, Cherie P. Erkmen, Fabrizio Galimberti, Tian Ma
Histone deacetylase inhibitor (HDACi; vorinostat) responses were studied in murine and human lung cancer cell lines and genetically engineered mouse lung cancer models. Findings were compared with a window of opportunity trial in aerodigestive tract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbef3689ed0ad10ea5eb76149024221a
https://doi.org/10.1158/1535-7163.c.6536251
https://doi.org/10.1158/1535-7163.c.6536251
Autor:
Ethan Dmitrovsky, Konstantin H. Dragnev, Sarah J. Freemantle, Yongli Guo, James DiRenzo, Hua Li, Jonathan M. Kurie, Gregory J. Tsongalis, David Johnstone, William Nugent, Bean N. Anyang, Jan H. Beumer, Lorenzo Sempere, Fadzai Chinyengetere, Vincent Memoli, Cherie P. Erkmen, Fabrizio Galimberti, Tian Ma
PDF file - 1690K, Supplemental Fig. 2: Pharmacodynamic effects of vorinostat in (A) murine ED-1 lung cancer cells and (B) human HOP62 lung cancer cells. Vorinostat dose-dependent effects were investigated by immunoblot analyses for Bcl-2 family membe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c16ff8bb04d8af2faaa58f1c1e0b76
https://doi.org/10.1158/1535-7163.22499764.v1
https://doi.org/10.1158/1535-7163.22499764.v1
Autor:
Lixin Yang, Suzette Blanchard, Thehang Luu, Yun Yen, Kyu pyo Kim, Bean N. Anyang, Jan H. Beumer, George Somlo, Arti Hurria
Publikováno v:
Breast Cancer Research and Treatment. 167:469-478
To translate promising preclinical data on the combination of vorinostat and ixabepilone for metastatic breast cancer (MBC) into clinical trials. We conducted a randomized two-arm Phase IB clinical trial of ascending doses of vorinostat and ixabepilo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c328fc1f0a12c15dda6b3a48fc214a
https://doi.org/10.1007/s10549-017-4516-x
https://doi.org/10.1007/s10549-017-4516-x
Autor:
Julie L. Eiseman, Jan H. Beumer, Bean N. Anyang, Robert A. Parise, Joseph M. Covey, Merrill J. Egorin
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:73-83
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is an alkylating agent with activity against renal cell carcinoma and is being evaluated clinically. To support clinical trials, we developed an LC-MS/MS assay to detect and quantitate BEN and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a7fac520ed6cf842a25745b306fcbcf
https://doi.org/10.1007/s00280-012-1980-1
https://doi.org/10.1007/s00280-012-1980-1
Autor:
Sandra Schamus, Hittu Matta, Preet M. Chaudhary, Aletheia Tamewitz, Bean N. Anyang, Vasu Punj
Publikováno v:
Oncogene
Kaposi's sarcoma (KS)-associated herpesvirus (KSHV)-encoded viral FLICE inhibitory protein (vFLIP) K13 is a potent activator of the nuclear factor-kappaB (NF-kappaB) pathway. In this study, we show that infection with KHSV and ectopic expression of K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4c006297686b2dbd86749aa73fce51
https://doi.org/10.1038/onc.2009.460
https://doi.org/10.1038/onc.2009.460
Publikováno v:
BMC Cancer
Background ATM and ATR are kinases implicated in a myriad of DNA-damage responses. ATM kinase inhibition radiosensitizes cells and selectively kills cells with Fanconi anemia (FA) gene mutations. ATR kinase inhibition sensitizes cells to agents that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd2c375430f5efb09dc38e1cb188dc00
https://pubmed.ncbi.nlm.nih.gov/26438152
https://pubmed.ncbi.nlm.nih.gov/26438152
Autor:
Ivana Gojo, Ming Tan, Hong-Bin Fang, Mariola Sadowska, Rena Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rakesh K. Srivastava, Igor Espinoza-Delgado, Douglas D. Ross
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(7)
Purpose: To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a32a7c861cc49ef67f9f5d1a2ec1c161
https://pubmed.ncbi.nlm.nih.gov/23403629
https://pubmed.ncbi.nlm.nih.gov/23403629